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Summary
Background: Usefulness and efﬁcacy of intravascular ultrasound (IVUS) for the
implantation of sirolimus-eluting stent (SES) is controversial. We investigated the pri-
mary and mid-term results of SES deployment with angiographic guidance comparing
with IVUS guidance, retrospectively.
Methods and results: SESs were deployed in 480 de novo lesions of 459 patients (341
lesions treated without IVUS and 139 lesions treated using IVUS); 368 lesions under-
went follow-up coronary angiography. Late luminal loss, in-stent restenosis (ISR)
rate and target lesion revascularization (TLR) rate were not signiﬁcantly different
between the non-IVUS group and the IVUS group. There was no acute thrombosis
or other major adverse cardiac events except for TLR in both groups. Multivariate
logistic regression analysis showed that SES implantation without IVUS was not an
independent risk factor for restenosis. On the other hand, in one case, target-vessel
revascularization was difﬁcult because of the mal-apposition of the SES previously
implanted without IVUS.
Conclusions: For lesions for which stent size and endpoint are decided from angio-
graphic information alone, angio-guided SES implantation is safe and provides a
good mid-term outcome that is comparable to the IVUS-guided SES stent deploy-
ment., while IVUS may be helpful to decide stent size for complex lesions and reduce
possible complications.
© 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
reserved.
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ackground
or percutaneous coronary intervention (PCI),
ntravascular ultrasound (IVUS) is useful for decid-
ng the adequate stent size and endpoint of the
rocedure [1,2]. In the bare metal stent era, max-
mal expansion of the stent without vessel injury
as thought to be important to reduce resteno-
is. Several studies reported that IVUS guidance
f bare metal stent implantation results in better
linical outcome compared with angiographic guid-
nce alone [3,4]. Recently, drug-eluting stents are
idely used. Several randomized trials have shown
hat the implantation of sirolimus-eluting stents
SESs) signiﬁcantly reduces the rates of resteno-
is and target-vessel revascularization by inhibiting
eointima formation [5—8]. In addition, several
ucceeding clinical studies in the Japanese popu-
ation showed the safety and efﬁcacy of SES for
andomly selected patients [9,10]. For the implan-
ation of SESs, it is recommended to fully cover the
laque, and adequately expand the stents without
al-apposition to prevent restenosis and thrombo-
is [11]. From such a point of view, several studies
uggest that IVUS is useful in SES implantation for
eciding an adequate stent size, and the endpoint
f the procedure, resulting in good short- and long-
erm outcomes [12—14]. On the other hand, some
nterventionists insist that IVUS is not necessary
o decide the stent size and to get the good out-
ome. In addition, when PCI is performed, IVUS is
ot always available for reasons such as restrictions
f manpower and procedure time. Usefulness and
ecessity of IVUS for stent implantation is a major
ssue of controversy regarding such interventional
rocedures.
In this study, to clarify the safety and efﬁcacy of
ES implantation with angiographic guidance alone,
e investigated the primary and mid-term results
f SES implantation using angiographic guidance
lone.
aterials and methods
atients
rom July 2004 to November 2006, 459 patients
with total of 480 lesions) underwent SES (Cypher
tent [Johnson and Johnson, New Brunswick, NJ,
SA]) implantation in their coronary arteries. Clin-
cal outcomes of the 459 patients at 8 months after
CI were investigated. As a rule, all patients under-
ent coronary angiography (CAG) 6—12 months
fter SES deployment for the purpose of clini-
al follow-up, not for the study. Among the 459
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atients, 348 patients (with total of 368 lesions)
nderwent follow-up CAG. For these 368 lesions,
uantitative coronary angiography (QCA) data at
he follow-up CAG were analyzed.
rimary and secondary endpoints
he primary endpoint was a composite of major
dverse cardiac events (death from cardiac causes,
yocardial infarction, and ischemia-driven revas-
ularization of the target lesion) within 8 months.
econdary endpoints included ischemia-driven
evascularization of the target lesion, target-
essel revascularization, and target-vessel failure
deﬁned as a composite of death from cardiac
auses, myocardial infarction, and ischemia-driven
arget-vessel revascularization).
Target lesion revascularization was deﬁned as
evascularization for a stenosis within the stent
r in the adjacent 5mm of the distal or proximal
dge of the stent. Revascularization of the target
esion was considered to be driven by ischemia if
he stenosis of any target lesion was at least 50% of
he diameter of the vessel on the basis of quan-
itative coronary angiography in the presence of
schemic signs or symptoms, or if the stenosis was
t least 75% of the diameter of the vessel even in
he absence of ischemic signs or symptoms.
Successful stenting was deﬁned as a ﬁnal stenosis
f less than 50% of the vessel diameter after implan-
ation of the study stent, and treatment success
as deﬁned as a ﬁnal stenosis of less than 50% of the
essel diameter with the use of any percutaneous
ntervention.
riteria for the use of IVUS
VUS was used to deploy SESs in speciﬁc lesions for
hich the determination of stent size or endpoint
as difﬁcult using angiographic information alone.
uantitative coronary angiography
oronary angiograms were digitally recorded at
aseline, post procedure, and at follow-up and
ere assessed at an angiographic core labora-
ory with an automated edge-detection system by
xperienced personnel unaware of the patients’
oronary risk proﬁles. All measurements were
erformed on cineangiograms recorded after the
ntracoronary or sublingual administration of nitro-
lycerin. The same single, worst-view projection
as used at all times. A contrast-ﬁlled non-tapered
atheter tip was used for calibration. The refer-
nce diameter was determined by interpolation.
uantitative measurements included the diameter
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Table 2 Lesion and procedural characteristics
Non-IVUS
(341 lesions)
IVUS (139
lesions)
P
Stent length per
lesion (mm)
20.2± 3.7 21.4± 3.7 0.17
Stent diameter
per lesion
(mm)
2.99± 0.36 2.93± 0.39 0.3320
of the reference vessel, the minimal luminal diam-
eter, and the extent of diametric stenosis (deﬁned
as the diameter of the reference vessel minus the
minimal luminal diameter, divided by the reference
diameter and multiplied by 100). In-stent resteno-
sis (ISR) was deﬁned as stenosis of at least 50% of
the minimal luminal diameter in the stented area
at the follow-up angiography. In-segment resteno-
sis was set as stenosis of at least 50% of the minimal
luminal diameter in the stented area and within the
margins of 5mm proximal and distal to each stent
edge.
Statistical analysis
Quantitative data are presented as mean with
standard deviation (S.D.), and categorical data
as frequencies (percentages). Continuous variables
were compared using the unpaired t-test. Binary
variables were compared by means of the Student’s
t-test. To identify the risk factors of restenosis,
multivariate logistic models were used. Odds ratios
were calculated as an estimate of relative risk of
restenosis associated with the possible risk factors
as well as use of IVUS. Statistical signiﬁcance was
deﬁned as P value of less than 0.05. All statistical
analyses were performed using JMP 5 software (SAS
Institute, Cary, North Carolina, USA).
Table 1 Baseline patient characteristics
Non-IVUS
(327 patients)
IVUS (132
patients)
P
Age (year) 66.0± 8.8 65.3± 9.9 0.41
Male (%) 89.0 90.9 0.54
Hypertension
(%)
57.5 54.5 0.57
Hyperlipidemia
(%)
64.5 69.7 0.29
Diabetes
mellitus (%)
44.6 47.7 0.55
Smoking (%) 66.1 68.9 0.55
Hemodialysis
(%)
9.2 12.1 0.34
Obesity (%) 40.1 43.9 0.45
Family history
(%)
17.1 20.5 0.40
Medication (%)
Statin 61.5 66.7 0.30
ACE inhibitor 14.1 12.9 0.74
ARB 14.7 16.7 0.59
Calcium
channel
blocker
30.0 22.7 0.12
-Blocker 12.2 13.6 0.68H. Fujimoto et al.
esults
aseline characteristics
or 327 of the 459 patients enrolled in the study,
ESs were deployed without IVUS guidance (non-
VUS group), while for the other 132 patients IVUS
as used for SES deployment (IVUS group). The
haracteristics of the patients included in the study
re shown in Table 1. The ratio of established coro-
ary risk factors was not statistically signiﬁcantly
ifferent between the non-IVUS group and the IVUSFinal balloon
diameter (mm)
3.02± 0.37 2.93± 0.39 0.12
Final inﬂation
pressure (atm)
13.8± 3.9 13.7± 4.4 0.80
Lesion length
(mm)
17.1± 5.9 18.2± 7.0 0.17
Number of stents 1.1 1.2 0.10
Kissing balloon
technique (%)
7.9 10.8 0.31
PTCRA (%) 4.1 5.8 0.43
Left anterior
descending
coronary
artery (%)
38.1 33.8 0.38
Left circumﬂex
artery (%)
25.4 26.5 0.80
Right coronary
artery (%)
31.2 35.6 0.36
Left main trunk
lesion (%)
0.9 2.9 0.09
Saphenous vein
graft lesion (%)
2.1 0 0.09
Type A (%) 1.5 0 0.15
Type B1 (%) 29.6 33.1 0.45
Type B2 (%) 34.9 32.4 0.60
Type C (%) 34.0 34.5 0.91
Bifurcated lesion
(%)
12.6 13.7 0.75
Chronic total
occlusion (%)
6.2 7.9 0.49
PTCRA: percutaneous transluminal coronary rotational
atherectomy.
Angiographically guided SES implantation
Table 3 Clinical events at 8 months after PCI
Non-IVUS
(n = 341)
IVUS
(n = 138)
P
Primary success
rate (%)
99.4 100 0.36
Acute or late
thrombosis (%)
0 0 —
Cardiac death 0 0 —
Myocardial
infarction (%)
0 0 —
Cerebrovascular
events (%)
0 0 —
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TLR: target lesion revascularization.
esions and procedural characteristics
he characteristics of the lesion and procedures
re shown in Table 2. Lesion and procedure charac-
eristics including stent size, stent length, number
f stents, etc., were not signiﬁcantly different
etween non-IVUS group and IVUS group.
linical outcome
linical outcomes at 8 months after PCI are shown
n Table 3. Stent implantation failed in one patient
n the non-IVUS group, because the stent could not
e optimally dilated due to severe calciﬁcation. As
ith the rest of the patients, neither acute nor late
hrombosis occurred in any patient. Cardiac death,
yocardial infarction, and cerebrovascular events
lso did not occur in any patient. The rates of target
esion revascularization (TLR) were 3.8% in the non-
VUS group and 3.6% in the IVUS group (P = 0.91).
In one patient who underwent SES implanta-
ion without IVUS, a new stenotic lesion but not
restenosis lesion was found in the distal por-
ion of the treated coronary artery at follow-up
AG. When target-vessel revascularization (TVR)
as performed, the guide wire passed through the
utside of the SES because of mal-apposition. The
roximal edge of the SES was crushed during the
VR procedure, and as a result, we had to implant
nother SES at the proximal portion of the previ-
usly implanted SES as well as at the distal new
esion.
ngiographic analysis
n all, 368 lesions (271 in the non-IVUS group and 97
n the IVUS group) underwent follow-up CAG. Angio-
raphic analyses data of the 368 lesions are shown
n Table 4. Reference diameter, minimal lumen
iameter, and percent diametric stenosis at pre-
i
i
d21
post-, and follow-up CAG were not statistically
igniﬁcantly different between the non-IVUS group
nd the IVUS group. Late loss was also not statis-
ically signiﬁcantly different between the non-IVUS
roup and IVUS group. In-stent restenosis rates of
he two groups were 4.8% in the non-IVUS group and
.2% in the IVUS group and they were not statisti-
ally signiﬁcantly different (P = 0.89).
ogistic regression analysis
e performed logistic regression analysis to deter-
ine the risk factors of restenosis after SES
mplantation. Univariate and multivariate logistic
egression analysis revealed that the hemodialy-
is and lesion length were statistically signiﬁcant
isk factors of restenosis (Table 5). However, SES
mplantation without IVUS was not an independent
isk factor for restenosis (odds ratio [OR] of IVUS
se for restenosis was 0.95, 95% conﬁdence interval
CI]: 0.31, 2.95; P = 0.93 from multivariate logistic
egression analysis).
iscussion
he major ﬁnding of our study is that SES implanta-
ion without IVUS is safe and effective in reducing
estenosis and target lesion revascularization as
ong as stent size can be decided angiographically.
VUS is a useful device that provides precise infor-
ation about the lesion length, vessel diameter,
nd other characteristics of the vessel. For the
mplantation of bare metal stents, full expansion of
he stent and obtaining large minimal lumen area
s thought to be important to reduce ISR. It was
eported that IVUS-guided stent implantation pro-
ides a larger stent lumen diameter, resulting in
better long-term outcome than stent implanta-
ion with angiographic guidance [3]. Thus far, much
ffort has been aimed during PCI at obtaining a
arge stent diameter without vessel injury. But SES
as a well-known efﬁcacy for suppression of neoin-
ima formation by a pharmaceutical mechanism,
nd it seems unnecessary to expand SES to a size
omparable to bare metal stents to ensure a good
utcome. Our data suggest that IVUS is not neces-
ary to adequately expand the SES and get a good
utcome in many cases. In a sense, it may be said
hat SESs have made the PCI procedure simpler and
asier than in the bare metal stent era.
But our data do not preclude the use of IVUS
n all SES implantations. IVUS is useful for SES
mplantation in lesions for which it is difﬁcult to
etermine the lesion length and vessel diameter
22 H. Fujimoto et al.
Table 4 Serial QCA data
Non-IVUS (271 lesions) IVUS (97 lesions) P
PCI-f/u CAG period (month) 7.8± 1.5 7.7± 1.1 0.70
Reference diameter (mm)
Preintervention 2.78± 0.30 2.79± 0.32 0.82
Postintervention 2.81± 0.31 2.82± 0.33 0.82
Follow-up 2.82± 0.31 2.82± 0.33 0.82
MLD (mm)
Preintervention 0.36± 0.22 0.38± 0.25 0.55
Postintervention
Proximal 2.63± 0.31 2.64± 0.33 0.87
In-stent 2.58± 0.31 2.59± 0.32 0.74
Distal 2.58± 0.31 2.59± 0.32 0.85
Follow-up
Proximal 2.47± 0.32 2.49± 0.33 0.55
In-stent 2.39± 0.39 2.37± 0.44 0.71
Distal 2.40± 0.36 2.42± 0.36 0.76
Diametric stenosis (%)
Preintervention 86.9± 7.7 86.4± 8.7 0.60
Postintervention
Proximal 6.2± 4.6 6.2± 4.7 0.92
In-stent 8.7± 4.6 8.5± 4.4 0.74
Distal 8.9± 4.9 8.8± 4.7 0.86
Follow-up
Proximal 12.5± 6.4 12.0± 4.9 0.46
In-stent 15.4± 12.0 16.0± 12.5 0.68
Distal 14.8± 8.8 14.5± 8.4 0.76
Late loss (mm)
Proximal 0.17± 0.12 0.15± 0.07 0.18
In-stent 0.19± 0.25 0.22± 0.40 0.40
Distal 0.15± 0.05 0.15± 0.05 0.66
Binary restenosis (%)
Proximal 0.4 0.0 0.55
In-stent 3.0 3.1 0.95
l
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sDistal 4.1
In-segment 4.8
from angiographic information alone, resulting in a
good primary and mid-term clinical outcome. For
example, for the PCI of left main trunk lesions,
precise evaluation of the distribution and amount
of plaque using IVUS was reported to be important
in deciding PCI strategy [15,16]. Precise evaluation
of lesion length and vessel diameter is also difﬁ-
cult in chronic total occlusion lesions and diffuse
lesions. In combination with IVUS, SESs may make
it possible to treat complex lesions that could not
be treated in the BMS era. It is therefore prudent
to select appropriate cases for IVUS-guided stent
implantation. In addition, we treated a patient
who underwent SES implantation without IVUS and
had difﬁculty in TVR because of mal-apposition of
the previously implanted SES. From this case, we
s
i
d
i1.0 0.15
5.2 0.89
earned that mal-apposition of SES may cause difﬁ-
ulty at TVR and much attention must be given to
void mal-apposition when SES is implanted without
VUS. IVUS may be helpful to reduce such incidental
omplications.
This study was a retrospective study with a small
umber of patients. Some of the lesions and pro-
edural characteristics were different between the
on-IVUS group and the IVUS group. But the main
bjective was not a rigid comparison of the result of
ES implantation using angiographic guidance ver-
us IVUS guidance. Rather, we intended to show the
afety and efﬁcacy of angiographically guided SES
mplantation except in cases where it is difﬁcult to
ecide stent size and endpoint from angiographic
nformation alone. Also, we intended to conﬁrm
Angiographically
guided
SES
im
plantation
23
Table 5 Logistic regression analysis for the coronary risk factors, lesion characteristics, and use of IVUS in relation to restenosis after SES implantation
Univariate logistic regression Multivariate logistic regression
OR (95% CI) P OR (95% CI) P
Male 0.59 (0.16—2.14) 0.42 0.52 (0.12—2.26) 0.26
Age (per year) 0.96 (0.92—1.01) 0.096 0.97 (0.92—1.03) 0.97
Hypertension 0.61 (0.24—1.59) 0.32 0.52 (0.18—1.49) 0.23
Diabetes mellitus 2.43 (0.89—6.62) 0.083 1.89 (0.63—5.66) 0.26
Hyperlipidemia 0.49 (0.19—1.27) 0—14 0.63 (0.22—1.78) 0.38
Smoking 1.37 (0.48—3.95) 0.56 1.03 (0.31—3.39) 0.97
Hemodialysis 4.80 (1.69—13.64) 0.0032 3.73 (1.13—12.38) 0.031
Lesion length (per mm) 1.07 (1.01—1.12) 0.013 1.06 (1.00—1.12) 0.045
Vessel diameter (per mm) 0.76 (0.17—3.50) 0.72 0.63 (0.11—3.57) 0.60
Chronic total occlusion 3.13 (0.84—11.68) 0.89 1.40 (0.15—1.32) 0.77
IVUS guidance 0.89 0.95 (0.31—2.91) 0.93
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that IVUS is an effective tool for deciding the stent
size and endpoint when it is difﬁcult to determine
this from angiographic information alone, and that
it ensures a good outcome. A randomized study
with a larger patient population will be necessary
to obtain adequate evidence.
Conclusion
In conclusion, with respect to lesions for which
stent size and endpoint are decided from angio-
graphic information alone, angio-guided SES
implantation is safe and provides a good mid-term
outcome comparable to that of IVUS-guided SES
deployment. However, IVUS may be a useful tool to
decide stent size for complex lesions and reduce
possible complications.
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